Prokineticin 2 signaling: PROKR1/PROKR2 laboratory assay design

1) Verify the active molecular species, not only the nominal sequence

PROK2 belongs to a small family of secreted proteins characterized by an N-terminal AVIT motif and a cysteine-rich mature domain. Those features are mechanistically important: an intact N terminus contributes to receptor activation, while the cysteine pattern constrains the folded structure. A mass that matches the predicted sequence does not establish correct disulfide connectivity, and a chromatographically pure preparation can still contain a biologically weak conformer.

Document the expressed or synthetic construct, signal-peptide removal, mature N terminus, sequence, tags, counterions or formulation additives, lot, concentration method, and freeze–thaw history. Confirm intact mass under nonreducing conditions and compare reduced and nonreduced chromatographic behavior. When recombinant material is used, test for aggregation and host-derived contaminants; cell-based assays are especially vulnerable to trace substances that alter calcium or MAP-kinase readouts.

Functional lot qualification should use a sequence-verified receptor line and a reference lot. Compare complete concentration–response curves rather than one high concentration. An N-terminal tag or fusion can interfere directly with the ligand’s activation domain, so tags used for purification should be removed when possible and the processed ligand requalified. PROK1 is a useful family comparator, but it is not an inert negative control because it can activate prokineticin receptors.

2) Resolve PROKR1 from PROKR2 with matched systems

PROKR1 and PROKR2 are homologous class A GPCRs, and PROK2 is not a subtype-exclusive ligand. A response in a cell that expresses both receptors cannot be assigned from the ligand name. Build matched single-receptor lines in the same host background, retain the parental line, and record receptor species, accession, complete construct, tag position, integration method, passage range, and culture conditions.

Expression matching matters because amplified endpoints can hide pharmacological differences. Quantify surface receptor with a validated extracellular epitope assay or ligand-binding method; total lysate abundance does not report delivery to the plasma membrane. Titrate expression to a range where the response is measurable without a large spare-receptor population, then repeat key comparisons at more than one receptor density.

Use genetic causality as the foundation: signal should be absent or greatly reduced in parental or receptor-knockout cells and restored by wild-type rescue. A receptor-selective antagonist can add evidence only after its concentration, equilibration time, species selectivity, and off-target effects have been established in the same assay. Cross-test PROK1 and PROK2 on both receptors on the same plate to expose ligand-by-receptor interactions and day-specific drift.

3) Triangulate Gq/11 signaling instead of relying on one calcium trace

A rapid intracellular-calcium assay is a practical primary readout for PROKR activation, but it is highly amplified and shaped by dye loading, cell density, basal calcium, plate temperature, injection mixing, receptor abundance, and intracellular-store capacity. Predefine baseline and integration windows, report both peak and area-under-the-curve where appropriate, and include a receptor-independent calcium-mobilizing control to distinguish receptor loss from a globally unresponsive cell.

Connect the calcium response to a more proximal measure. Suitable pairings include Gq recruitment, heterotrimer dissociation, inositol-monophosphate accumulation, or phospholipase-C pathway biosensors. Pertussis toxin, selective G-protein depletion, or pharmacological inhibitors can test pathway contributions, but each perturbation needs viability and pathway-competence controls. Inhibitor sensitivity alone is not receptor identification.

Monnier and colleagues used ligand-evoked intracellular calcium in transfected HEK-293 cells to compare wild-type and mutant PROKR2 receptors.^[1] Their design illustrates both the usefulness and the limitation of the endpoint: calcium provides a sensitive functional screen, but interpreting a low signal required separate measurements of surface targeting and ligand binding. The same layered logic should be applied to wild-type receptor comparisons.

Downstream ERK phosphorylation or transcriptional reporters may extend the experiment, but they integrate many pathways and feedback loops. Measure an early time course, normalize within a validated linear range, and require receptor dependence. A single late phospho-ERK point is insufficient to distinguish direct G-protein signaling from secondary autocrine events.

4) Classify receptor variants by mechanism

A low-response PROKR2 variant can fail for at least four different reasons: poor synthesis or stability, defective delivery to the cell surface, impaired ligand recognition, or inefficient coupling after binding. These mechanisms are not interchangeable, and a functional assay alone cannot identify them.

Monnier and colleagues examined ten PROKR2 missense variants in a recombinant system. Several variants showed poor surface targeting, one disrupted ligand binding, and others were interpreted as coupling-defective; most had reduced signaling, whereas M323I did not show the same loss under the tested conditions.^[1] Coexpression experiments also did not support a dominant-negative effect for the tested mutants. This result argues for a minimum variant panel consisting of total expression, surface expression, ligand binding, and signaling normalized to the surface receptor population.

Run wild-type and variant receptors in parallel from the same transfection batch, include mock-transfected cells, and sequence-verify every construct. If tags are necessary, demonstrate that the tagged wild-type receptor retains ligand affinity and signaling. Rescue of a trafficking-defective variant by lower culture temperature or a chaperone may be informative, but it does not establish normal pharmacology; the rescued surface receptor still requires binding and coupling measurements.

Do not equate an in vitro activity change with a complete organismal phenotype. Variant interpretation must account for receptor dosage, tissue expression, developmental timing, genetic background, and the limits of the recombinant host. The laboratory result should be stated narrowly: for example, reduced PROK2-evoked calcium at matched surface expression, not a predicted clinical outcome.

5) Measure desensitization, internalization, and recovery explicitly

Acute activation and sustained signaling are different experimental questions. Generate second-pulse experiments after defined wash intervals to quantify desensitization and recovery. Pair functional recovery with receptor localization using an independently validated extracellular tag, surface-labeling assay, or imaging approach. Ligand fluorescence alone cannot establish receptor internalization because labeled protein may adsorb to membranes or enter cells by a receptor-independent route.

For imaging, include parental cells, excess unlabeled competitor, free-dye or linker controls, and surface-quenching or acid-wash steps. Report temperature, acquisition interval, exposure, segmentation rules, and whether the tag changes pharmacology. Quantify surface loss, intracellular accumulation, and recycling separately; a falling plasma-membrane signal may reflect internalization, shedding, photobleaching, or epitope masking.

Time also matters upstream. Ligand adsorption, oxidation, aggregation, or proteolysis can change the effective exposure during a long assay. Sample the actual medium at the beginning and end of the experiment and measure intact PROK2 recovery with an appropriate analytical method. A stable receptor reporter does not compensate for an unstable ligand preparation.

6) Connect recombinant pharmacology to native systems without overreach

Cheng and colleagues identified rhythmic Prok2 expression in the suprachiasmatic nucleus and receptor expression in major target nuclei, supporting PROK2 as an output signal from the circadian clock.^[2] Prosser and colleagues later showed that targeted Prokr2 disruption in mice altered the organization and strength of circadian activity while organotypic SCN slices retained competent molecular oscillation.^[3] Together, these experiments distinguish clock output coordination from the generation of the core cellular oscillator.

That distinction guides experimental design. A native circadian study should measure phase, period, amplitude, and waveform rather than treating “rhythm” as a single endpoint. Record light schedule, zeitgeber or circadian time, sex, age, entrainment history, sampling density, and genotype. Use reporter rhythms or molecular clock markers alongside output measures, and analyze repeated observations with methods appropriate for time-series data.

Outside the SCN, receptor distribution and cell composition change the meaning of a response. A study of intestinal inflammation localized PKR1 to enteric and sensory neurons and PKR2 to sensory ganglia in the tested preparations; PROK2 raised intracellular calcium in cultured neurons, and an antagonist blocked that signal.^[4] This provides a useful example of moving from tissue expression to cellular function, but it does not make receptor attribution universal across species or preparations.

For native cells or tissues, combine RNA localization with validated protein, binding, or functional evidence. Include cell-type markers, receptor knockout or knockdown where feasible, viability controls, and same-preparation positive controls. State conclusions at the level measured: receptor-dependent calcium mobilization, neuronal excitability, or clock-output organization under defined laboratory conditions.

7) A reproducible PROK2 assay workflow

1. Lock reagent identity. Record the mature sequence, processing, formulation, concentration method, aggregation state, and functional lot performance.
2. Build matched receptor backgrounds. Use the same host, verified constructs, quantified surface expression, and a parental line.
3. Establish causality. Require loss in receptor-null cells and restoration by wild-type rescue before assigning a subtype.
4. Triangulate signaling. Combine a proximal Gq/11 measure with calcium or IP1 and a pathway-competence control.
5. Deconvolve variants. Measure expression, trafficking, binding, and coupling rather than labeling every low-response construct “loss of function.”
6. Resolve kinetics. Predefine stimulation, wash, second-pulse, imaging, and ligand-recovery intervals.
7. Validate at the right scale. Match native endpoints and conclusions to cell type, tissue, species, circadian phase, and perturbation.

A rigorous PROK2 study separates ligand quality, receptor identity, and pathway amplification. When those layers are measured independently, calcium transients, receptor variants, trafficking behavior, and native circadian observations can be connected without asking one endpoint to prove the entire mechanism.